Slide
Centre Interdisciplinaire
de Recherche et d’Innovation
en Cybersécurité et Société
de Recherche et d’Innovation
en Cybersécurité et Société
1.
Katzman, M. A.; Bleau, P.; Blier, P.; Chokka, P.; Kjernisted, K.; Ameringen, M. Van; Antony, M. M.; Bouchard, S.; Brunet, A.; Flament, M.; Rabheru, K.; Grigoriadis, S.; Richter, P. M. A.; Mendlowitz, S.; O'Connor, K.; Robichaud, M.; Walker, J. R.; Asmundson, G.; Klassen, L. R.; Lam, R. W.; McIntyre, R. S.; Szpindel, I.
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders Article de journal
Dans: BMC Psychiatry, vol. 14, no SUPPL.1, 2014, ISSN: 1471244X (ISSN), (Publisher: BioMed Central Ltd.).
Résumé | Liens | BibTeX | Étiquettes: agoraphobia, Anxiety disorder, Anxiety Disorders, benzodiazepine derivative, buspirone, Canada, clinical trial, clomipramine, comorbidity, duloxetine, escitalopram, fluoxetine, fluvoxamine, fluvoxamine maleate, GAD, generalized anxiety disorder, guidelines, human, Humans, obsessive compulsive disorder, Obsessive-Compulsive Disorder, OCD, panic, Panic Disorder, paroxetine, periodic medical examination, pharmacotherapy, Post-Traumatic, posttraumatic stress disorder, practice guideline, Practice Guidelines as Topic, psychotherapy, PTSD, recommendations, review, sertraline, social anxiety disorder, social phobia, special populations, Specific phobia, Stress Disorders, venlafaxine
@article{katzman_canadian_2014,
title = {Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders},
author = {M. A. Katzman and P. Bleau and P. Blier and P. Chokka and K. Kjernisted and M. Van Ameringen and M. M. Antony and S. Bouchard and A. Brunet and M. Flament and K. Rabheru and S. Grigoriadis and P. M. A. Richter and S. Mendlowitz and K. O'Connor and M. Robichaud and J. R. Walker and G. Asmundson and L. R. Klassen and R. W. Lam and R. S. McIntyre and I. Szpindel},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84903778611&doi=10.1186%2f1471-244X-14-S1-S1&partnerID=40&md5=4787fc6f97c204c1428770a5e4a57a00},
doi = {10.1186/1471-244X-14-S1-S1},
issn = {1471244X (ISSN)},
year = {2014},
date = {2014-01-01},
journal = {BMC Psychiatry},
volume = {14},
number = {SUPPL.1},
abstract = {Background: Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.Methods: These guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE, PsycINFO, and manual searches (1980-2012). Treatment strategies were rated on strength of evidence, and a clinical recommendation for each intervention was made, based on global impression of efficacy, effectiveness, and side effects, using a modified version of the periodic health examination guidelines.Results: These guidelines are presented in 10 sections, including an introduction, principles of diagnosis and management, six sections (Sections 3 through 8) on the specific anxiety-related disorders (panic disorder, agoraphobia, specific phobia, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder), and two additional sections on special populations (children/adolescents, pregnant/lactating women, and the elderly) and clinical issues in patients with comorbid conditions.Conclusions: Anxiety and related disorders are very common in clinical practice, and frequently comorbid with other psychiatric and medical conditions. Optimal management requires a good understanding of the efficacy and side effect profiles of pharmacological and psychological treatments. © 2014 Katzman et al.},
note = {Publisher: BioMed Central Ltd.},
keywords = {agoraphobia, Anxiety disorder, Anxiety Disorders, benzodiazepine derivative, buspirone, Canada, clinical trial, clomipramine, comorbidity, duloxetine, escitalopram, fluoxetine, fluvoxamine, fluvoxamine maleate, GAD, generalized anxiety disorder, guidelines, human, Humans, obsessive compulsive disorder, Obsessive-Compulsive Disorder, OCD, panic, Panic Disorder, paroxetine, periodic medical examination, pharmacotherapy, Post-Traumatic, posttraumatic stress disorder, practice guideline, Practice Guidelines as Topic, psychotherapy, PTSD, recommendations, review, sertraline, social anxiety disorder, social phobia, special populations, Specific phobia, Stress Disorders, venlafaxine},
pubstate = {published},
tppubtype = {article}
}
Background: Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.Methods: These guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE, PsycINFO, and manual searches (1980-2012). Treatment strategies were rated on strength of evidence, and a clinical recommendation for each intervention was made, based on global impression of efficacy, effectiveness, and side effects, using a modified version of the periodic health examination guidelines.Results: These guidelines are presented in 10 sections, including an introduction, principles of diagnosis and management, six sections (Sections 3 through 8) on the specific anxiety-related disorders (panic disorder, agoraphobia, specific phobia, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder), and two additional sections on special populations (children/adolescents, pregnant/lactating women, and the elderly) and clinical issues in patients with comorbid conditions.Conclusions: Anxiety and related disorders are very common in clinical practice, and frequently comorbid with other psychiatric and medical conditions. Optimal management requires a good understanding of the efficacy and side effect profiles of pharmacological and psychological treatments. © 2014 Katzman et al.
2.
Bouchard, S.; Côté, S.; St-Jacques, J.; Robillard, G.; Renaud, P.
Effectiveness of virtual reality exposure in the treatment of arachnophobia using 3D games Article de journal
Dans: Technology and Health Care, vol. 14, no 1, p. 19–27, 2006, ISSN: 09287329 (ISSN), (Publisher: IOS Press).
Résumé | Liens | BibTeX | Étiquettes: arachnophobia, Araneae, article, avoidance behavior, clinical article, computer program, exposure, female, game, Games, human, male, phobia, priority journal, Self Concept, Specific phobia, treatment outcome, virtual reality
@article{bouchard_effectiveness_2006,
title = {Effectiveness of virtual reality exposure in the treatment of arachnophobia using 3D games},
author = {S. Bouchard and S. Côté and J. St-Jacques and G. Robillard and P. Renaud},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-33644903496&doi=10.3233%2fthc-2006-14103&partnerID=40&md5=3ba6883c3fa7fed039b0cc3bff10879e},
doi = {10.3233/thc-2006-14103},
issn = {09287329 (ISSN)},
year = {2006},
date = {2006-01-01},
journal = {Technology and Health Care},
volume = {14},
number = {1},
pages = {19–27},
abstract = {Buying or creating a virtual reality (VR) software is very costly. A less expensive alternative could be to modify already existing 3D computer games. The goal of this study is to assess the effectiveness of in virtuo exposure in the treatment of arachnophobia using modified 3D games. Participants were 10 women and 1 man. Virtual worlds were created using the game editor of a 3D computer game (Half-Life™), modified to offer graduals hierarchies of fearful stimuli (spiders). Analyses revealed significant improvement between pre and post results on the behavioral avoidance test, the Spider Beliefs Questionnaire, and perceived self-efficacy. These promising results suggest that therapy using virtual reality exposure via a modified computer game is useful in the treatment of arachnophobia. © 2006 - IOS Press and the authors. All rights reserved.},
note = {Publisher: IOS Press},
keywords = {arachnophobia, Araneae, article, avoidance behavior, clinical article, computer program, exposure, female, game, Games, human, male, phobia, priority journal, Self Concept, Specific phobia, treatment outcome, virtual reality},
pubstate = {published},
tppubtype = {article}
}
Buying or creating a virtual reality (VR) software is very costly. A less expensive alternative could be to modify already existing 3D computer games. The goal of this study is to assess the effectiveness of in virtuo exposure in the treatment of arachnophobia using modified 3D games. Participants were 10 women and 1 man. Virtual worlds were created using the game editor of a 3D computer game (Half-Life™), modified to offer graduals hierarchies of fearful stimuli (spiders). Analyses revealed significant improvement between pre and post results on the behavioral avoidance test, the Spider Beliefs Questionnaire, and perceived self-efficacy. These promising results suggest that therapy using virtual reality exposure via a modified computer game is useful in the treatment of arachnophobia. © 2006 - IOS Press and the authors. All rights reserved.